Investment
Features
FeesSafety
Academy
More
Pluang+

Compare McKesson Corporation (MCK) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance

McKesson CorporationTrade
T-Rex 2X Long MSTR Daily Target ETFTrade

Price performance (Past 24H)

Key statistics

McKesson Corporation vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? McKesson Corporation trades at $877.9 (market cap $102.45B), while T-Rex 2X Long MSTR Daily Target ETF trades at $1.82. The key difference: McKesson Corporation pays a 0.43% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none, and McKesson Corporation is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.

MCKMSTU
Market Cap
$102.45B
Sector
HealthLeveraged / Inverse
52-Week High
$995.69$74.30
52-Week Low
$663.17$1.46
Enterprise Value
$108.99B
Dividend Yield
0.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

McKesson Corporation

McKesson (MCK) trades at $877.87, down 0.23% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company reported robust Q1 2027 results with EPS of $9.93 beating estimates by 20% year-over-year, driven by specialty drug growth and oncology performance. Revenue reached $105.4 billion, up 8%, prompting management to raise full-year adjusted EPS guidance. Analyst consensus remains strongly bullish with 24 buy ratings and a $990.67 price target, representing 13% upside potential.

MCK presents a compelling investment case with consistent earnings beats, raised guidance, and strong operational cash flow of $6.9 billion projected for 2026. Key risks include margin pressure from the low 1.12% net income margin, high accounts payable of $55.33 billion, and negative shareholder equity of -$2.07 billion. The stock's valuation at 24.19 P/E appears reasonable given growth prospects, but investors should monitor debt levels and pharmaceutical pricing dynamics.

T-Rex 2X Long MSTR Daily Target ETF

MSTU is trading at $1.81, down 4.23% today, with a bearish technical outlook showing 15 sell signals versus 1 buy signal. The ETF has experienced significant value erosion, with recent articles highlighting a 98% decline from November 2024 levels. A 10:1 reverse stock split is scheduled for August 2026, reflecting the fund's substantial challenges amid volatile market conditions.

The outlook remains highly risky given the leveraged structure's daily compounding effects and severe historical losses. While potential exists for recovery if underlying assets rebound, the fund's track record suggests continued vulnerability to market volatility. Investors should approach with extreme caution given the documented 95% annual decline and structural risks.

Returns comparison

Trailing returns across standard periods

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK

About T-Rex 2X Long MSTR Daily Target ETF

MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.

Read more on MSTU